Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

hetic molecule) of uroguanylin developed by Callisto scientists, and is proprietary to Callisto. Guanilib has been demonstrated to be superior to uroguanylin in its biological activity, protease stability and pH characteristics, and is currently undergoing pre-clinical animal studies as a treatment for gastrointestinal (GI) diseases and GI inflammation. Animal model data on Guanilib previously demonstrated anti-inflammatory activity in a number of mouse-models of ulcerative colitis, and the drug is currently being evaluated in animal models of GI disorders. Callisto plans to initiate clinical trials of Guanilib in early 2008.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory ac
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Laparoscopes Market Outlook ... North America Laparoscopes Market Outlook to ... America Laparoscopes Market Outlook to 2020", provides key ... The report provides value, in millions of US ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... China , Aug. 28, 2014 ... TPI ), a pharmaceutical company that specializes in ... generics and active pharmaceutical ingredients (API) today updates ... Company,s Qionglai Facility (QLF). The ... Practice (GMP) dataset for China Food & Drug ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Reportlinker.com announces that a new market research ... Patient Self-Monitoring: Devices, Markets, Players ... http://www.reportlinker.com/p0581171/Patient-Self-Monitoring-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic The ... serum levels is deemed to be a ...
... A new patent covering tumor suppression technologies, including the ... awarded to The University of Texas System ... to the discovery that chromosome 3p21.3 genes act as ... also known as FUS1, the anti-cancer agent in ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Genprex Announces New Patent Issuance in Japan 2
(Date:8/28/2014)... Valero Renewable Fuels Company, LLC, a ... and the Ports of Indiana hosted Lt. Gov. Sue ... a Port Appreciation and Welcome Celebration commemorating the restart ... “The opening of Valero’s ethanol facility at the ... win for the State of Indiana,” Ellspermann said. “When ...
(Date:8/28/2014)... 2014 Gurnick Academy of Medical Arts ... is re-accredited for the 5 years of the accreditation ... (ARMRIT). , “We are very proud to have ... program to make sure we provide the best experience ... in MRI field nowadays and I look forward to ...
(Date:8/28/2014)... Norton HealthDay Reporter THURSDAY, ... sending electrical currents through the scalp to a specific network ... a day. In a small study of healthy young ... certain networks involved in memory. That, in turn, boosted participants, ... after the brain stimulation. During TMS, an electromagnetic coil ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... Chicago, IL (PRWEB) August 28, 2014 ... IT Supplement shows that while most hospitals utilize a ... of health care information technology is still a challenge. ... in the August issue of Health Affairs , ... Health Forum’s Health Care Data Center, as well as ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3
... her down but along with her, her families too have to ... brain //and breast has taken its toll on Ellen who is ... the illness. Her family could seem to do nothing to ease ... quarters- the palliative care team at Dartmouth Hitchcock Medical Center. ...
... get married is a waste of breath, a US expert ... // ,William Smith, the vice president of the Sexuality, ... a six-year study commissioned by the US Congress found that ... on pushing sexual abstinence outside marriage had had no discernible ...
... day of reckoning is only getting closer for the Bush ... //The most recent, is the one cited by the American ... the information provided by the federally sponsored ‘Abstinence Only Sex ... way of a lengthy document compiled by Dr. John Santelli, ...
... ‘chemo brain’ that chemotherapy patients complain about, is finally ... especially women have for years informed their doctors about ... to concentrate, difficulty retrieving words, trouble with multitasking and ... edge. Once brushing such complaints aside, these very people, ...
... breakthrough method of blood test to diagnose Parkinson disease. This ... before the symptoms arrive. The test is done by a ... Melbourne University specialists. ,They have also created a ... it can screen many types of PD and monitor treatment ...
... is no evidence that antioxidant supplements interfere with ... a recent systematic //review of the use of ... increase survival rates, tumor response, and the patient’s ... implications for patients whose oncologists discourage the use ...
Cached Medicine News:Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Chemo Brain- Nothing Forgettable About It 2Health News:Chemo Brain- Nothing Forgettable About It 3Health News:New Blood Test to Diagnose Parkinson Disease 2Health News:Antioxidants May Aid Chemotherapy Patients 2